Condition: Prostate Cancer · Sponsor: VA Office of Research and Development
This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA targeted radiopharmaceutical therapy and cessation of castration, and then followed by testosterone replacement, is an effective treatment for metastatic castration resistant prostate cancer. All patients will be treated with stereotactic ablative radiotherapy and PSMA targeted radiopharmaceutical therapy with cessation of castration. Half of patients are randomized to either receive, or not receive, subsequent testosterone replacement.
This description comes directly from the study's public registry record.
Nicholas G Nickols, MD PhD · (310) 478-3711 · nicholas.nickols@va.gov
Matthew B Rettig, MD · (310) 478-3711 · matthew.rettig@va.gov
Always discuss trial participation with your own doctor first.
| VA Greater Los Angeles Healthcare System, West Los Angeles, CA | West Los Angeles, California, United States | Recruiting |
| Edward Hines Jr. VA Hospital, Hines, IL | Hines, Illinois, United States | Recruiting |
| Richard L. Roudebush VA Medical Center, Indianapolis, IN | Indianapolis, Indiana, United States | Recruiting |
| VA Ann Arbor Healthcare System, Ann Arbor, MI | Ann Arbor, Michigan, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06084338